Primary Biliary Cholangitis Highlights from EASL 2023
Primary Biliary Cholangitis Highlights from EASL 2023
Liver disease experts share their perspectives on key Primary Biliary Cholangitis data from EASL 2023
Liver disease experts share their perspectives on key Primary Biliary Cholangitis data from EASL 2023
Dr Emma Culver, Prof. Gideon Hirschfield, Ms Kath Houghton, Mr Robert Mitchell-Thain
In these two podcasts, medical experts and a patient representative share their perspectives on new Primary Biliary Cholangitis (PBC) data from EASL 2023.
In podcast 1, physicians Dr Emma Culver and Prof. Gideon Hirschfield discuss the evidence of cancer risk associated with PBC, how liver stiffness progression is associated with prognosis; and outcomes and response prediction in second-line therapy.
In podcast 2, CEO of the PBC Foundation, Robert Mitchell-Thain, and autoimmune specialist nurse Kath Houghton explore the impact of PBC symptoms and new instruments for assessing them. They also discuss data highlighting the importance of the current move toward normalisation of liver biomarkers and take a look at some early data on future therapies and therapeutic targets.
Transcripts, with details of the presentations covered, are available for download.
Dr Emma Culver
Hepatologist
John Radcliffe Hospital and University of Oxford
United Kingdom (UK)
Prof. Gideon Hirschfield
Professor of Medicine
Division of Gastroenterology, University of Toronto
Canada
Ms Kath Houghton
Specialist Nurse
Newcastle Hospitals NHS Foundation Trust
United Kingdom (UK)
Mr Robert Mitchell-Thain
Advocacy
PBC Foundation
United Kingdom (UK)
PBC Highlights from EASL: Episode 1
Podcast | 
30 min
|
Jun 2023
download resources
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
PBC Highlights from EASL 2023: Episode 2
Podcast | 22 min
|
Jun 2023
download resources
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
Clinical Takeaways
-
When treating people living with PBC, the goal is to aim for normal liver blood tests and normal quality of life
-
Emerging therapies are hoped to both significantly address biochemical and symptom control in PBC
-
Pruritus and fatigue can be devastating, and upcoming trials importantly are addressing alleviation of patient symptom burden as a priority
-
In the expected future treatment landscape, optimised markers of prognosis, response, and quality of life will become increasingly important
This programme is endorsed by 
This educational programme is supported by an Independent Medical Education Grant from Ipsen
Other programmes of interest
35 min
